JPH 227
Alternative Names: JPH227Latest Information Update: 28 Feb 2022
At a glance
- Originator J-Pharma
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Diagnosis) in Japan (Parenteral)
- 25 Jan 2019 Clinical trials in Cancer in Japan (Parenteral) before January 2019 (J-Pharma Pipeline)